Avedro, which sells ophthalmic medical systems used in treating corneal disorders, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Waltham, MA-based company was founded in 2002 and booked $24 million in sales for the 12 months ended September 30, 2018. It plans to list on the Nasdaq under the symbol AVDR. Avedro filed confidentially on November 15, 2018. BofA Merrill Lynch and J.P. Morgan are the joint bookrunners on the deal. No pricing terms were disclosed.
